PT Darya-Varia Laboratoria Tbk Logo

PT Darya-Varia Laboratoria Tbk

DVLA.JK

(2.0)
Stock Price

1.670 IDR

7.85% ROA

11.81% ROE

11.11x PER

Market Cap.

1.881.600.000.000 IDR

0.09% DER

6.43% Yield

8.49% NPM

PT Darya-Varia Laboratoria Tbk Stock Analysis

PT Darya-Varia Laboratoria Tbk Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PT Darya-Varia Laboratoria Tbk Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (0%), which means it has a small amount of debt compared to the ownership it holds

2 Dividend

The company's consistent dividend payouts over the past five years exemplify its strong commitment to providing shareholders with reliable returns, making it an attractive investment option.

3 ROE

The stock's ROE falls within an average range (5.82%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (4.34%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 PBV

The stock's PBV ratio (1.32x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

6 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (22.874) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

10 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

11 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

PT Darya-Varia Laboratoria Tbk Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PT Darya-Varia Laboratoria Tbk Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Buy

PT Darya-Varia Laboratoria Tbk Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PT Darya-Varia Laboratoria Tbk Revenue
Year Revenue Growth
2009 869.170.910.000
2010 929.196.665.000 6.46%
2011 972.297.437.000 4.43%
2012 1.087.379.869.000 10.58%
2013 1.101.684.170.000 1.3%
2014 1.103.821.775.000 0.19%
2015 1.306.098.136.000 15.49%
2016 1.451.356.680.000 10.01%
2017 1.575.647.308.000 7.89%
2018 1.699.657.296.000 7.3%
2019 1.813.020.278.000 6.25%
2020 1.829.699.557.000 0.91%
2021 1.900.893.602.000 3.75%
2022 1.917.041.442.000 0.84%
2023 1.468.334.704.000 -30.56%
2023 1.890.887.506.000 22.35%
2024 2.219.716.404.000 14.81%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PT Darya-Varia Laboratoria Tbk Research and Development Expenses
Year Research and Development Expenses Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 24.158.361.000 100%
2018 23.172.448.000 -4.25%
2019 23.668.051.000 2.09%
2020 26.303.077.000 10.02%
2021 40.300.245.000 34.73%
2022 25.013.285.000 -61.12%
2023 31.953.052.000 21.72%
2023 30.658.194.000 -4.22%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PT Darya-Varia Laboratoria Tbk General and Administrative Expenses
Year General and Administrative Expenses Growth
2009 90.766.429.000
2010 79.875.792.000 -13.63%
2011 89.493.149.000 10.75%
2012 97.578.979.000 8.29%
2013 109.234.252.000 10.67%
2014 107.800.052.000 -1.33%
2015 133.205.786.000 19.07%
2016 125.797.244.000 -5.89%
2017 57.069.681.000 -120.43%
2018 54.015.003.000 -5.66%
2019 54.749.669.000 1.34%
2020 71.240.669.000 23.15%
2021 73.926.947.000 3.63%
2022 83.257.725.000 11.21%
2023 95.869.436.000 13.16%
2023 96.152.125.000 0.29%
2024 100.939.088.000 4.74%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PT Darya-Varia Laboratoria Tbk EBITDA
Year EBITDA Growth
2009 121.320.233.000
2010 132.759.100.000 8.62%
2011 160.177.738.000 17.12%
2012 196.165.866.000 18.35%
2013 167.079.175.000 -17.41%
2014 94.470.525.000 -76.86%
2015 121.607.173.000 22.32%
2016 206.369.517.000 41.07%
2017 249.181.145.000 17.18%
2018 297.077.572.000 16.12%
2019 320.201.642.000 7.22%
2020 246.498.315.000 -29.9%
2021 246.462.109.000 -0.01%
2022 233.136.121.000 -5.72%
2023 49.309.624.000 -372.8%
2023 244.230.064.000 79.81%
2024 290.367.224.000 15.89%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PT Darya-Varia Laboratoria Tbk Gross Profit
Year Gross Profit Growth
2009 536.075.954.000
2010 587.646.776.000 8.78%
2011 623.278.353.000 5.72%
2012 651.109.890.000 4.27%
2013 660.656.077.000 1.44%
2014 585.219.682.000 -12.89%
2015 677.733.217.000 13.65%
2016 801.437.752.000 15.44%
2017 893.956.419.000 10.35%
2018 925.409.702.000 3.4%
2019 973.481.977.000 4.94%
2020 931.988.668.000 -4.45%
2021 995.768.212.000 6.41%
2022 1.006.123.382.000 1.03%
2023 720.665.524.000 -39.61%
2023 942.410.751.000 23.53%
2024 1.122.849.300.000 16.07%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PT Darya-Varia Laboratoria Tbk Net Profit
Year Net Profit Growth
2009 72.272.233.000
2010 110.880.522.000 34.82%
2011 120.915.340.000 8.3%
2012 148.909.089.000 18.8%
2013 125.796.473.000 -18.37%
2014 80.929.476.000 -55.44%
2015 107.894.430.000 24.99%
2016 152.083.400.000 29.06%
2017 162.249.293.000 6.27%
2018 200.651.968.000 19.14%
2019 221.783.249.000 9.53%
2020 162.072.984.000 -36.84%
2021 146.505.337.000 -10.63%
2022 149.375.011.000 1.92%
2023 14.025.728.000 -965.01%
2023 146.336.365.000 90.42%
2024 207.473.904.000 29.47%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PT Darya-Varia Laboratoria Tbk Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2009 64
2010 99 35.35%
2011 108 8.33%
2012 133 18.8%
2013 112 -18.75%
2014 73 -53.42%
2015 97 24.74%
2016 136 28.68%
2017 145 6.21%
2018 180 18.99%
2019 198 9.6%
2020 145 -37.5%
2021 131 -10.77%
2022 133 2.26%
2023 0 0%
2023 131 100%
2024 185 29.73%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PT Darya-Varia Laboratoria Tbk Free Cashflow
Year Free Cashflow Growth
2009 -15.893.489.000
2010 78.020.621.000 120.37%
2011 6.424.858.000 -1114.36%
2012 64.264.311.000 90%
2013 51.994.971.000 -23.6%
2014 43.843.542.000 -18.59%
2015 177.213.618.000 75.26%
2016 -8.487.610.000 2187.91%
2017 192.341.650.000 104.41%
2018 -18.859.594.000 1119.86%
2019 213.583.369.000 108.83%
2020 43.776.630.000 -387.89%
2021 348.340.849.000 87.43%
2022 122.283.811.000 -184.86%
2023 11.269.825.000 -985.06%
2023 110.405.517.000 89.79%
2024 -22.455.901.000 591.65%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PT Darya-Varia Laboratoria Tbk Operating Cashflow
Year Operating Cashflow Growth
2009 5.688.757.000
2010 130.614.145.000 95.64%
2011 72.518.015.000 -80.11%
2012 119.207.439.000 39.17%
2013 106.931.180.000 -11.48%
2014 104.436.317.000 -2.39%
2015 214.166.823.000 51.24%
2016 187.475.539.000 -14.24%
2017 230.738.193.000 18.75%
2018 26.628.428.000 -766.51%
2019 272.538.844.000 90.23%
2020 106.583.179.000 -155.71%
2021 435.333.430.000 75.52%
2022 182.497.211.000 -138.54%
2023 109.185.785.000 -67.14%
2023 132.013.255.000 17.29%
2024 -3.912.587.000 3474.07%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PT Darya-Varia Laboratoria Tbk Capital Expenditure
Year Capital Expenditure Growth
2009 21.582.246.000
2010 52.593.524.000 58.96%
2011 66.093.157.000 20.43%
2012 54.943.128.000 -20.29%
2013 54.936.209.000 -0.01%
2014 60.592.775.000 9.34%
2015 36.953.205.000 -63.97%
2016 195.963.149.000 81.14%
2017 38.396.543.000 -410.37%
2018 45.488.022.000 15.59%
2019 58.955.475.000 22.84%
2020 62.806.549.000 6.13%
2021 86.992.581.000 27.8%
2022 60.213.400.000 -44.47%
2023 97.915.960.000 38.51%
2023 21.607.738.000 -353.15%
2024 18.543.314.000 -16.53%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PT Darya-Varia Laboratoria Tbk Equity
Year Equity Growth
2009 554.921.528.000
2010 640.602.050.000 13.37%
2011 727.917.390.000 12%
2012 841.546.479.000 13.5%
2013 914.702.952.000 8%
2014 962.431.483.000 4.96%
2015 973.517.334.000 1.14%
2016 1.079.579.612.000 9.82%
2017 1.116.300.069.000 3.29%
2018 1.200.261.863.000 7%
2019 1.306.078.988.000 8.1%
2020 1.326.287.143.000 1.52%
2021 1.380.798.261.000 3.95%
2022 1.403.620.581.000 1.63%
2023 1.404.432.093.000 0.06%
2023 1.413.287.528.000 0.63%
2024 1.450.098.035.000 2.54%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PT Darya-Varia Laboratoria Tbk Assets
Year Assets Growth
2009 783.613.064.000
2010 854.109.991.000 8.25%
2011 928.290.993.000 7.99%
2012 1.074.691.476.000 13.62%
2013 1.190.054.288.000 9.69%
2014 1.236.247.525.000 3.74%
2015 1.376.278.237.000 10.17%
2016 1.531.365.558.000 10.13%
2017 1.640.886.147.000 6.67%
2018 1.682.821.739.000 2.49%
2019 1.829.960.714.000 8.04%
2020 1.986.711.872.000 7.89%
2021 2.085.904.980.000 4.76%
2022 2.009.139.485.000 -3.82%
2023 2.043.484.913.000 1.68%
2023 2.007.726.972.000 -1.78%
2024 2.228.391.751.000 9.9%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PT Darya-Varia Laboratoria Tbk Liabilities
Year Liabilities Growth
2009 228.691.536.000
2010 213.507.941.000 -7.11%
2011 200.373.603.000 -6.55%
2012 233.144.997.000 14.06%
2013 275.351.336.000 15.33%
2014 273.816.042.000 -0.56%
2015 402.760.903.000 32.02%
2016 451.785.946.000 10.85%
2017 524.586.078.000 13.88%
2018 482.559.876.000 -8.71%
2019 523.881.726.000 7.89%
2020 660.424.729.000 20.68%
2021 705.106.719.000 6.34%
2022 605.518.904.000 -16.45%
2023 639.052.820.000 5.25%
2023 594.439.444.000 -7.51%
2024 778.293.716.000 23.62%

PT Darya-Varia Laboratoria Tbk Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1781.85
Net Income per Share
151.23
Price to Earning Ratio
11.11x
Price To Sales Ratio
0.94x
POCF Ratio
9.64
PFCF Ratio
21.43
Price to Book Ratio
1.3
EV to Sales
0.81
EV Over EBITDA
5.65
EV to Operating CashFlow
8.23
EV to FreeCashFlow
18.3
Earnings Yield
0.09
FreeCashFlow Yield
0.05
Market Cap
1.882 Bil.
Enterprise Value
1.607 Bil.
Graham Number
2098.96
Graham NetNet
306.12

Income Statement Metrics

Net Income per Share
151.23
Income Quality
1.15
ROE
0.12
Return On Assets
0.08
Return On Capital Employed
0.15
Net Income per EBT
0.76
EBT Per Ebit
0.92
Ebit per Revenue
0.12
Effective Tax Rate
0.24

Margins

Sales, General, & Administrative to Revenue
0.05
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.51
Operating Profit Margin
0.12
Pretax Profit Margin
0.11
Net Profit Margin
0.08

Dividends

Dividend Yield
0.06
Dividend Yield %
6.43
Payout Ratio
0.8
Dividend Per Share
108

Operating Metrics

Operating Cashflow per Share
174.26
Free CashFlow per Share
78.38
Capex to Operating CashFlow
0.55
Capex to Revenue
0.05
Capex to Depreciation
1.68
Return on Invested Capital
0.13
Return on Tangible Assets
0.08
Days Sales Outstanding
156.88
Days Payables Outstanding
56.69
Days of Inventory on Hand
150.84
Receivables Turnover
2.33
Payables Turnover
6.44
Inventory Turnover
2.42
Capex per Share
95.87

Balance Sheet

Cash per Share
246,48
Book Value per Share
1.294,73
Tangible Book Value per Share
1232.29
Shareholders Equity per Share
1294.73
Interest Debt per Share
1.18
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-0.97
Current Ratio
2.57
Tangible Asset Value
1.380 Bil.
Net Current Asset Value
833 Bil.
Invested Capital
1484530039000
Working Capital
984 Bil.
Intangibles to Total Assets
0.03
Average Receivables
818 Bil.
Average Payables
149 Bil.
Average Inventory
426158302000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PT Darya-Varia Laboratoria Tbk Dividends
Year Dividends Growth
2006 55
2008 45 -22.22%
2009 45 0%
2010 45 0%
2011 30 -50%
2012 32 3.23%
2013 47 34.04%
2014 22 -113.64%
2015 70 68.57%
2016 35 -100%
2017 100 65%
2018 107 6.54%
2019 107 0%
2020 107 0%
2021 112 4.46%
2022 116 3.45%
2023 121 4.13%
2024 65 -86.15%

PT Darya-Varia Laboratoria Tbk Profile

About PT Darya-Varia Laboratoria Tbk

PT Darya-Varia Laboratoria Tbk engages in the manufacture and trading of pharmaceutical products and cosmetics in Indonesia. It operates in three segments: Prescription Drugs, Consumer Health Products, and Export and Toll Manufacturing Services. It provides various prescription and consumer health products in antibiotic, antiparasit, antiseptic, anti-fungal, cough and cold, cardiology, central nervous system, gastro-hepatology, somatic, vitamin and food supplement, women healthcare, ear healthcare, and derma medic areas. The company also exports its products to Malaysia, Myanmar, the Philippines, Singapore, Vietnam, and Mongolia. The company was founded in 1976 and is headquartered in Jakarta, Indonesia. PT Darya-Varia Laboratoria Tbk is a subsidiary of Blue Sphere Singapore Pte. Ltd.

CEO
Mr. Celso Paz Lim
Employee
1.273
Address
Tower C
Jakarta, 12430

PT Darya-Varia Laboratoria Tbk Executives & BODs

PT Darya-Varia Laboratoria Tbk Executives & BODs
# Name Age
1 Mr. Celso Paz Lim
Finance Director & Director
70
2 Mr. Setyo Dumadi
Treasury
70
3 Ms. Widya Olivia Tobing
Head of Legal & Corporate Secretary
70
4 Mr. Dandan Darmawan
Director of Human Resources Development
70
5 Mr. Angelito Celso Corsame Racho Jr.
Director of Manufacturing, Supply Chain, Research & Development and Director
70
6 Mr. Chandra Ngesahkan Halomoan Tarigan
Head of Internal Audit Unit
70

PT Darya-Varia Laboratoria Tbk Competitors